CRO医药企业数字化转型对企业绩效的影响研究——以泰格医药为例

Research on the Impact of Digital Transformation in CRO Pharmaceutical Enterprises on Corporate Performance—Taking Tigermed as an Example

摘要: 得益于数字化技术的迅猛发展和政府对数字经济的政策支持，数字化转型成为数字技术驱动经济社会系统性重构的核心进程。同时在全球医药研发外包(CRO)行业竞争加剧与集采常态化的背景下，CRO企业利用数字化转型提升自身竞争力的动力愈发强烈，数字化转型已成为企业突破发展瓶颈、提升绩效的核心战略。本文以泰格医药为研究对象，选取案例分析法，探讨泰格医药的数字化转型对企业绩效的影响，分析数字化转型对企业绩效的影响路径及作用机制，帮助CRO企业更加清晰地了解数字化的效果。研究发现，数字化转型显著提升了企业的盈利能力、偿债能力、营运能力和成长能力，在数字化转型下企业取得更好的绩效。

Abstract: Benefiting from the rapid development of digital technologies and policy support for the digital economy from governments, digital transformation has become a core process driven by digital technologies to systematically restructure the economy and society. Simultaneously, against the backdrop of intensifying global competition in the pharmaceutical R&D outsourcing (CRO) industry and the normalization of centralized procurement, CRO enterprises are increasingly motivated to enhance their competitiveness through digital transformation. Digital transformation has emerged as a critical strategy for enterprises to overcome development bottlenecks and improve performance. This study takes Tigermed as a research subject, employing a case study method to explore the impact of its digital transformation on corporate performance. It analyzes the pathways and mechanisms through which digital transformation influences performance, aiming to provide clearer insights for CRO enterprises into the effects of digitalization. The findings reveal that digital transformation significantly enhances corporate profitability, debt-paying ability, operational capability, and growth potential, leading to improved performance under digital transformation.